allied safe lock
NEW YORK (Reuters Health) – Adding veliparib to platinum-based chemotherapy for first-line treatment of current smokers with advanced squamous non-small-cell lung cancer (NSCLC) did not significantly improve overall survival in a phase-3 study.
However, the LP52 signature may identify a subgroup of patients “likely to derive benefit” from the addition of veliparib to chemotherapy, researchers report in the Journal of Clinical Oncology.
“Squamous NSCLC has limited therapeutic options. Veliparib is a potent, oral PARP1/2 inhibitor that enhances the activity of platinum-based chemotherapy regimens in solid tumors,” note Dr. Suresh S. Ramalingam, buy buspar no prescription visa with Winship Cancer Institute, Atlanta, and colleagues.
For their study, they randomly allocated 970 patients (57% current smokers) with untreated, advanced squamous NSCLC to carboplatin and paclitaxel with veliparib 120 mg or placebo twice a day for up to six cycles.
There was no significant overall survival (OS) benefit with veliparib in current smokers (the primary outcome), with a median OS of 11.9 months with veliparib versus 11.1 months with placebo (hazard ratio, 0.905; 95% confidence interval, 0.744 to 1.101).
In the overall population, OS favored veliparib over placebo, with median OS of 12.2 versus 11.2 months (HR, 0.853; 95% CI, 0.747 to 0.974), with no difference in progression-free survival (median, 5.6 months per group).
Among the 360 patients with biomarker-evaluable tumor samples, veliparib had a favorable effect on OS in the LP52-positive population (median OS, 14.0 vs. 9.6 months; HR, 0.66; 95% CI, 0.49 to 0.89).
“Despite no benefit of adding veliparib to carboplatin and paclitxel in current smokers being observed, risk of death was decreased by 34% in the LP52-positive population with veliparib versus placebo,” the authors write in their paper.
“These findings indicate that this biomarker-defined subgroup may derive greater benefit from poly (ADP-ribose) polymerase inhibition and support the use of biomarkers to identify treatment-sensitive subgroups,” they conclude.
Funding for the study was provided by AbbVie, which makes veliparib. Several authors have disclosed financial relationships with the company.
SOURCE: https://bit.ly/3DQZQ6r Journal of Clinical Oncology, online August 26, 2021.
Source: Read Full Article